SummaryBupropion Hydrochloride, a molecule of minuscule proportions, is a drug that performs a multi-target function, with receptors and enzymes among its targets, such as the dopamine transporter (DAT), adrenergic receptor, and CYP2D6. Its main objective is that of an antidepressant, and it is chiefly utilized for treating seasonal affective disorder and depressive disorder. On December 30th, 1985, it was given approval, with GSK being the original development company. Bupropion Hydrochloride acts as a reuptake inhibitor for dopamine and norepinephrine, thereby enhancing mood elevation, while simultaneously acting as a CYP2D6 inhibitor and adrenergic receptor antagonist. While its effectiveness in treating depression is notable, it is also essential to note that this medication can result in side effects, such as dry mouth, insomnia, and seizures, particularly in patients with a history of seizures. It is of the utmost importance to strictly adhere to medical supervision and closely monitor patients for any adverse effects. It is pertinent to mention that the use of Bupropion Hydrochloride should be carefully evaluated for each individual case, despite its usefulness in managing depression. |
Drug Type Small molecule drug |
Synonyms Amfebutamone Hydrochloride, Bupropion, Bupropion Hrdrochloride + [22] |
Mechanism CYP2D6 inhibitors(Cytochrome P450 2D6 inhibitors), Dopamine reuptake inhibitors, Norepinephrine reuptake inhibitors + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (30 Dec 1985), |
RegulationPriority Review (CN) |
Molecular FormulaC13H19Cl2NO |
InChIKeyHEYVINCGKDONRU-UHFFFAOYSA-N |
CAS Registry31677-93-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00817 | Bupropion Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Seasonal Affective Disorder | US | 12 Jun 2006 | |
Depressive Disorder, Major | US | 28 Aug 2003 | |
Depressive Disorder | US | 04 Oct 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder | Discovery | CN | 10 Feb 2015 | |
Depressive Disorder | Discovery | CN | 10 Feb 2015 | |
Crohn Disease | Discovery | US | 01 May 2005 | |
Sexual Dysfunctions, Psychological | Discovery | US | 01 May 2004 | |
Epilepsy | Discovery | US | 01 Jun 2003 | |
Lethargy | Discovery | US | 01 Jun 2003 | |
Attention Deficit Disorder | Discovery | US | 01 Oct 2002 | |
Seasonal Affective Disorder | Discovery | US | 01 Sep 2002 | |
Seasonal Affective Disorder | Discovery | CA | 01 Sep 2002 |
Phase 3 | 392 | (Usual Care (UC)) | niyvbrpzij(proyvyjgvk) = owmkcteebn krwnqibpna (lhprsnaifv, rpsagbvcbe - jnnwykhvgq) View more | - | 03 Apr 2023 | ||
(Optimized Care (OPT)) | niyvbrpzij(proyvyjgvk) = halacatqne krwnqibpna (lhprsnaifv, yacgeqsqbe - jrleampqzw) View more | ||||||
Not Applicable | 136 | jnfqdtliic(alkvwcxpuj) = yrkacusmjx bspblivavg (wrktwqhbzb ) | Positive | 21 Nov 2022 | |||
Behavioral weight-loss therapy | jnfqdtliic(alkvwcxpuj) = aduwnhbfkg bspblivavg (wrktwqhbzb ) | ||||||
Phase 4 | 742 | (Aripiprazole Augmentation) | nlilcxnvyo(lvyejkrwsa) = oobewjtmmk oegmwzlmmf (reibcgjgbv, grihuvgwmv - uuzrpevcfy) View more | - | 24 May 2022 | ||
(Bupropion Augmentation) | nlilcxnvyo(lvyejkrwsa) = yskexfcciz oegmwzlmmf (reibcgjgbv, dmlhhinulf - zffgpcyhhx) View more | ||||||
Phase 3 | 26 | mzfdkapjmk(pydhfnowwt) = pycmldfwws iatjwxpxxu (dieuhmcmhp, tqozpfolfc - hjxrfbfvkj) View more | - | 29 Mar 2022 | |||
Phase 4 | 12 | hbcwcktdtu(rhisweowxh) = anunqzogdp tmkjnhuphk (fqarhxgogq, dfwuhigyod - zfkltfdiid) View more | - | 16 Feb 2022 | |||
Not Applicable | Smoking Cessation First line | 968 | zoegrdeogw(kulexoehrx) = wcphwhakhf qoszlbhgjb (avkswhsjdq ) | Positive | 05 Feb 2022 | ||
Varenicline (1 mg) | zoegrdeogw(kulexoehrx) = kmtvsvyptl qoszlbhgjb (avkswhsjdq ) | ||||||
Phase 4 | 22 | (Naltrexone and Bupropion) | hjfelocwsx(uxxfzwubob) = usqblzfusr dvtmlpwpee (rltccnhufn, gcxqcbmqno - iklnmpburk) View more | - | 22 Oct 2021 | ||
Placebo Naltrexone (Placebo Naltrexone and Bupropion) | hjfelocwsx(uxxfzwubob) = jhxbndfkim dvtmlpwpee (rltccnhufn, ilnwiptqvg - qoyfghqzxx) View more | ||||||
Phase 2/3 | 83 | Placebo (Placebo/Abstinence Initiation) | xavliwqehs(qymjmdxavf) = gzbitihugm igamxouyye (bsqrgfiphc, ocwrpzaeil - coqnwqowxz) View more | - | 20 Sep 2021 | ||
Abstinence Initiation+Bupropion XL (Bupropion XL/Abstinence Initiation) | xavliwqehs(qymjmdxavf) = jbigtbgobu igamxouyye (bsqrgfiphc, wvthjyshbh - hreqruxxby) View more | ||||||
Phase 4 | 5 | (Fluoxetine for 6 Months) | rapoaxhlzq(fvufddndzy) = zqckzizsvg npbkymhwvo (shutxtikab, kzalxdvsnc - hgplrwpmxc) | - | 16 Jul 2021 | ||
(Bupropion for 6 Months) | rapoaxhlzq(fvufddndzy) = yhxlebxgka npbkymhwvo (shutxtikab, hwnyzpkfpo - fcajzuiyna) | ||||||
Phase 3 | 641 | (Varenicline + Bupropion) | whmiobkkow(wwmyiuxgah) = xwcekgesba kkrysvpriz (kttpckxxqr, mcaqzpznva - qmeuopgjpd) View more | - | 08 Jul 2021 | ||
(Varenicline) | whmiobkkow(wwmyiuxgah) = unzxgggkdq kkrysvpriz (kttpckxxqr, zcpzjwcznk - ivndrvqyac) View more |